1.Eosinophil Inflammation of Nasal Polyp Tissue: Relationships with Matrix Metalloproteinases, Tissue Inhibitor of Metalloproteinase-1, and Transforming Growth Factor-beta1.
Hae Sim PARK ; Sun Sin KIM ; Hyun Ah KIM ; Yu Jin SUH ; Soo Keol LEE ; Dong Ho NAHM ; Young Mok LEE
Journal of Korean Medical Science 2003;18(1):97-102
Eosinophil and mast cell infiltrations are consistent findings in nasal polyp tissue. Previous studies have shown that matrix metalloproteinases (MMPs) may be involved in eosinophil infiltration in airway mucosa of asthmatic patients, and that transforming growth factor-beta1 (TGF-beta1) induces extracellular matrix deposition in nasal polyp tissue. The aim of this study was to evaluate the role of MMPs and tissue-inhibitor of metalloproteinase-1 (TIMP-1) in association with TGF-beta1, eosinophils and mast cell activation in nasal polyp tissue. Nasal polyp tissues from 20 patients who underwent polypectomies were collected and prepared into tissue homogenate. Eosinophil cationic protein (ECP) and tryptase levels were measured by CAP system (Pharmacia, Sweden). MMP-2, MMP-9, TIMP-1 and TGF-beta1 levels were measured by enzyme-liked immunosorbent assay. MMP-2 was the predominant form of MMPs, followed by MMP-9 and TIMP-1. There were significant correlations between ECP, and MMP-9, MMP-2, TGF-beta1 and tryptase, but not with TIMP-1. Significant correlations were noted between tryptase, and MMP-2, MMP-9, and TGF-beta1, but not with TIMP-1. Close correlations were noted between TGF-beta1, and MMP-9 and MMP-2, but not with TIMP-1. MMP-2, MMP-9, and TGF-beta1 may contribute to eosinophil and mast cell migrations into nasal polyp tissue.
Adult
;
Asthma/complications
;
Blood Proteins/analysis
;
Chemotaxis, Leukocyte
;
Eosinophilia/etiology
;
Eosinophilia/metabolism*
;
Eosinophilia/pathology
;
Eosinophils/physiology
;
Female
;
Gelatinase A/analysis
;
Gelatinase A/physiology*
;
Gelatinase B/analysis
;
Gelatinase B/physiology*
;
Human
;
Male
;
Mast Cells/physiology
;
Middle Aged
;
Nasal Polyps/chemistry*
;
Nasal Polyps/etiology
;
Nasal Polyps/pathology
;
Rhinitis/metabolism
;
Rhinitis/pathology
;
Ribonucleases*
;
Serine Endopeptidases/analysis
;
Tissue-Inhibitor of Metalloproteinase-1/analysis
;
Tissue-Inhibitor of Metalloproteinase-1/physiology*
;
Transforming Growth Factor beta/analysis
;
Transforming Growth Factor beta/physiology*
2.The Role of Angiostatin, Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9 and 12 in the Angiogenesis of Hepatocellular Carcinoma.
Sook KIM ; Ho Sung PARK ; Hyun Jin SON ; Woo Sung MOON
The Korean Journal of Hepatology 2004;10(1):62-72
BACKGROUND/AIMS: Tumor angiogenesis, a major requirement for tumor growth and metastasis, is regulated by pro- and anti-angiogenic factors. Hepatocellular carcinoma (HCC) has become a common malignant tumor worldwide. It is characterized by a high vascularity. METHODS: We studied the immunohistochemical expression of angiostatin, vascular endothelial cell growth factor (VEGF), matrix metalloproteinase (MMP)-9 and MMP-12, and the relationship between these results and the microvessel density (MVD) in 48 HCC specimens. To determine whether HCC cells express angiostatin per se, we examined the expression of angiostatin, MMP-9 and MMP-12 by Western blotting in four HCC cell lines. RESULTS: Expression of angiostatin and MMP-12 (but not MMP-9) were strongly correlated with decreased MVD in HCCs (P=0.006, P=0.038, respectively). VEGF positive tumors showed a significantly higher MVD than VEGF negative tumors (P=0.01). We divided the 48 cases into the following four groups: group A, angiostatin (+), MMP-9 or -12 (+), and VEGF (-); group B, angiostatin (-) and VEGF (-); group C, angiostatin (+), MMP-9 or -12 (+), and VEGF (+); group D, angiostatin (-) and VEGF (+). There was a significant correlation with MVD among these groups (P<0.001). Angiostatin was detected by Western blotting in 2 out of 4 HCC cell lines and was associated with plasminogen and MMP expression. CONCLUSIONS: These results indicate that angiogenesis in HCC is a complex process involving multiple factors including angiostatin, VEGF, and MMP. Our results suggest that angiostatin is generated by MMP-mediated proteolysis of plasminogen in HCC cells.
Adult
;
Aged
;
Angiogenesis Inhibitors/analysis/physiology
;
Angiostatins/analysis/physiology
;
Carcinoma, Hepatocellular/*blood supply/chemistry
;
English Abstract
;
Female
;
Gelatinase B/analysis/physiology
;
Humans
;
Liver Neoplasms/*blood supply/chemistry
;
Male
;
Metalloendopeptidases/analysis/physiology
;
Middle Aged
;
Neovascularization, Pathologic/metabolism/*physiopathology
;
Vascular Endothelial Growth Factor A/analysis/physiology
3.Ox-LDL suppresses PMA-induced MMP-9 expression and activity through CD36-mediated activation of PPAR-gamma.
Kyoung Jin LEE ; Hyun A KIM ; Pyeung Hyeun KIM ; Han soo LEE ; Kyung Ran MA ; Jeong Hyun PARK ; Dae Joong KIM ; Jang Hee HAHN
Experimental & Molecular Medicine 2004;36(6):534-544
During chronic inflammatory response, mono- cytes/macrophages produce 92-kDa matrix metalloproteinase-9 (MMP-9), which may contribute to their extravasation, migration and tissue remodeling. Activation of peroxisome proliferator- activated factor receptor-gamma (PPAR-gamma) has been shown to inhibit MMP-9 activity. To evaluate whether ox-LDL, a PPAR-gamma activator, inhibits PMA-induced MMP-9 expression and activity, and if so, whether CD36 and PPAR-gamma are involved in this process, we investigated the effect of ox-LDL on MMP-9 expression and activity in PMA-activated human monocytic cell line U937. PMA-induced MMP-9 expression and activity were suppressed by the treatment with ox-LDL (50 micrigram/ml) or PPAR-gamma activators such as troglitazone (5 micrometer), ciglitazone (5 micrometer), and 15d- PGJ2 (1 micrometer) for 24 h. This ox-LDL or PPAR-gamma activator-mediated inhibition of micrometer P-9 activity was diminished by the pre-treatment of cells with a blocking antibody to CD36, or PGF2a (0.3 micrometer), which is a PPAR-gamma inhibitor, as well as overexpression of a dominant-negative form of CD36. Taken together, these results suggest that ox-LDL suppresses PMA-induced MMP-9 expression and activity through CD36-mediated activation of PPAR-gamma.
Antibodies, Blocking/pharmacology
;
Antigens, CD36/immunology/*physiology
;
Cells, Cultured
;
Chromans/pharmacology
;
Gelatinase B/antagonists & inhibitors/genetics/*metabolism
;
Humans
;
Lipoproteins, LDL/pharmacology/*physiology
;
Monocytes/drug effects/*enzymology/metabolism
;
NF-kappa B/antagonists & inhibitors
;
PPAR gamma/*metabolism
;
Prostaglandin D2/*analogs & derivatives/pharmacology
;
RNA, Messenger/analysis/metabolism
;
Research Support, Non-U.S. Gov't
;
Tetradecanoylphorbol Acetate/antagonists & inhibitors/pharmacology
;
Thiazolidinediones/pharmacology
;
Transcription, Genetic/drug effects